Elafibranor (GFT505)
Primary Biliary Cholangitis (PBC)
Key Facts
About Genfit
Founded in 1999, Genfit has established itself as a key player in liver disease R&D, leveraging deep expertise in nuclear receptor biology to develop therapeutics and diagnostics. Its strategy is validated by the Phase 3 success of elafibranor in PBC and the commercial launch of its NIS4® diagnostic. The company is now executing a dual-track strategy of advancing its late-stage asset towards regulatory approval while building a commercial diagnostics business.
View full company profileAbout Genfit
Founded in 1999, Genfit has established itself as a key player in liver disease R&D, leveraging deep expertise in nuclear receptor biology to develop therapeutics and diagnostics. Its strategy is validated by the Phase 3 success of elafibranor in PBC and the commercial launch of its NIS4® diagnostic. The company is now executing a dual-track strategy of advancing its late-stage asset towards regulatory approval while building a commercial diagnostics business.
View full company profileTherapeutic Areas
Other Primary Biliary Cholangitis (PBC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Setanaxib | Calliditas Therapeutics | Phase 2 |
| CNP Program | COUR Pharmaceuticals | Unknown |
| RO-7011789 (Nidufexor) | Rohto Pharmaceutical | Phase 2 |
| IQIRVO® (elafibranor) | Ipsen | Marketed / Late-stage Study |
| CNP-104 | Ironwood Pharmaceuticals | Preclinical |